Organization · Venture Capital
Nextech Invest
Nextech Invest is a biotechnology investment firm based in Zurich, Switzerland, specializing in oncology and precision medicine. The firm invests in companies at various stages of development across North America and Europe.
Overview
What Nextech Invest does
What Nextech Invest is
Nextech Invest is a biotechnology investment firm based in Zurich, Switzerland, specializing in oncology and precision medicine. The firm invests in companies at various stages of development across North America and Europe.
How it participates in the startup ecosystem
The current public profile supports funder capabilities. Each capability below is shown separately so organization identity and role-specific information do not get conflated.
Operational profile
Organization status and context
Organization status describes the entity itself. Funding and program availability appear within the relevant capability profile.
- Operational status
- Active
- Organization type
- Venture Capital
- Founded
- Founded in 1998
- Approximate age
- About 28 years
- Structured capabilities
- Funder
- Last reviewed
- April 22, 2026
Official channels
Find Nextech Invest elsewhere
Open the official website or a supported primary organization account.
Capability profile
Nextech Invest as a funder
Investment thesis
Nextech Invest focuses on biotechnology investments, particularly in oncology and precision medicine, supporting companies through critical scientific validation and development stages.
Focus narrative
Nextech Invest specializes in investments within the biotechnology sector, emphasizing precision medicine and oncology. The firm provides critical support during key moments of scientific validation and company development, ensuring that innovative therapies have the resources and guidance needed to succeed.
Value beyond capital
Nextech Invest adds value to its portfolio companies through deep scientific diligence and access to a cancer-research advisory board comprised of experts from top academic centers. This support helps companies navigate the complexities of drug development and enhances their chances of success in the competitive biotechnology landscape.
Focus and fit
- Stages
- Friends and Family · Angel · Accelerator · Pre-seed · Seed · Seed+ · Series A · Series A+ · Series B · Series B+ · Series C · Series C+ · Series D · Series E · Series F · Growth Equity · Pre-IPO · Ipo
- Regions
- North AmericaEurope
Availability
- Currently deploying
- Yes
Portfolio and track record
- Recorded portfolio count
- 5
- Recorded notable exits
- Arvinas, Blueprint Medicines, and IDEAYA Biosciences
Portfolio context
Nextech Invest's diverse portfolio includes notable biotechnology companies such as AIRNA, which develops RNA-editing medicines; Tubulis, focusing on antibody-drug conjugates for oncology; ORIC Pharmaceuticals, which works on overcoming resistance in cancer therapies; and Circle Pharma, known for developing macrocycle drugs for cancer treatment. Other portfolio companies include A2 Biotherapeutics, Alpha-9 Oncology, Alterome Therapeutics, Arvinas, Blueprint Medicines, and Revolution Medicines.
Common questions
What to know about Nextech Invest
Upseed classifies Nextech Invest under the Venture Capital organization type. Its current public profile includes funder capabilities.
Source and update disclosure
Know what this page is based on
Source basis
Public organization and program material, official websites, and structured Upseed records.
Last reviewed
April 22, 2026
Known limits
Capability profiles appear only when a structured public profile also contains decision-useful role evidence. Terms and availability can change.
Upseed is an independent guide. It is not affiliated with or endorsed by the organization described on this page.